A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants

NCT06370728 · Completed

Last updated 2026-05-28

This clinical trial tests how the drug orforglipron interacts with carbamazepine in healthy participants by measuring the levels of orforglipron in the blood.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design open-label (no blinding) basic-science study

Participants 30 people

Who can join Ages 21–70 · all sexes Healthy volunteers accepted.

Timeline Started 2024-05 · est. completion 2024-07

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06370728 ↗

Description as written by the study sponsor.

The main purpose of this study is to assess the effect of carbamazepine on the amount of orforglipron in the bloodstream and how long it takes the body to get rid of orforglipron when given orally in healthy study participants. The safety and tolerability of orforglipron and carbamazepine when given separately or together will also be evaluated. The study may last up to approximately 77 days for each participant.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally
Carbamazepine Drug

Administered orally

Main thing measured	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC [0-∞]) of Orforglipron
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06370728 ↗